Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting in National Harbor, MD

Austin, Texas – Date: November 11, 2014 – Asuragen, Inc., a leading molecular diagnostics company, will present at the upcoming Association for Molecular Pathology (AMP) 20th Annual Meeting, November 12-15, 2014 in National Harbor, MD. The Company will showcase its broad expertise in diagnostic products and development efforts in the areas of oncology, genetic testing and next-generation sequencing (NGS).

“Launching at AMP the first of our NGS workflow solutions, QuantideX® DNA Assay sets the stage for a number of products we’re bringing to market over the next year,” said Matthew McManus, MD, PhD, President and CEO of Asuragen. “Our commitment to patient care and serving our laboratory customers clearly shows in the suite of innovative diagnostic and lab-enabling kits we have, and will continue to, develop and offer.”

In conjunction with the AMP Annual Meeting, Asuragen will host two corporate workshops on November 12, 2014. The corporate workshop day is an opportunity for all AMP attendees, and the public, to learn about the latest scientific advances. In the first corporate workshop at 8:00 am, Dr. Deborah Hall, a neurologist from Rush University Medical School, will describe her clinical research that links FMR1 genetic variations revealed using AmplideX® PCR technologies with movement disorders in the aging populace. In the second corporate workshop at noon, Dr. Gary Latham, VP for Research and Technology Development at Asuragen, will discuss the new QuantideX® DNA Assay, which helps guide the input of low-quality and low-quantity FFPE and FNA DNA into NGS target enrichment and improve the accuracy of mutation detection.

Asuragen’s technologies will also be featured in three scientific posters that reflect the company’s breadth in creating technology solutions for diagnostic applications. One study describes the utility of AmplideX® FMR1 PCR combined with NGS to unlock a complete molecular analysis of the fragile X gene and provide a comprehensive analysis of matched blood and cell-line DNA materials. A second study applies AmplideX® PCR innovations to quantify GC-rich hexanucleotide repeats in the C9orf72 gene. This novel repeat marker is a genetic bridge between ALS and FTD, and has been associated with other neurodegenerative disorders such as Alzheimer’s disease. Finally, data from a third study will be presented that describes a comprehensive and cross-platform NGS workflow that is suitable for FFPE, FNA, and biofluid samples and can report both DNA and RNA cancer markers using a single, unified method.

For more information on Asuragen’s activities at the AMP Annual Meeting stop by booth #529.


Media Contact
Lynne Hohlfeld
SVP, Corporate Development and Chief Financial Officer
Asuragen, Inc.

Back To